Core Insights - Yiling Pharmaceutical has achieved significant innovation milestones in 2025, including the acceptance of its first classic prescription product, Banxia Baizhu Tianma Granules, and the approval for clinical trials of the chemical drug G201-Na Capsule [1] - The company has successfully launched Qifang Bitong Tablets in both domestic and Macau markets, indicating a potential expansion in sales [1] Group 1: Innovation and Product Development - Yiling Pharmaceutical is a leading representative in the modernization of traditional Chinese medicine, operating in three main business segments: traditional Chinese medicine, chemical medicine, and health products [2] - The company has launched 17 patented traditional Chinese medicines, covering eight major clinical disease systems, with 11 products included in the national medical insurance catalog [2] - From 2020 to 2024, Yiling Pharmaceutical has developed five new drugs, averaging one new drug per year, which is notable compared to the national average of fewer than 10 new traditional Chinese medicines approved annually [2] Group 2: Research and Development Pipeline - The company has a robust pipeline of research projects, with two traditional Chinese medicines approved for production, six in clinical trial phases, and over a hundred hospital preparations as reserves for new drug development [5] - A detailed list of ongoing research projects includes various traditional Chinese medicines targeting conditions such as allergic rhinitis, chronic cholecystitis, and pediatric colds, with several in different stages of clinical trials [3][4] Group 3: Strategic Expansion and Internationalization - Yiling Pharmaceutical is focusing on high-quality development by increasing innovation investments and accelerating high-end and international industrial layouts, aiming to create a globally influential industrial cluster [6] - The company's core products are now available in over 50 countries and regions, reflecting its solid internationalization efforts [6] - Yiling has developed a unique theory system on "Luo Disease," which has gained international recognition, and has published the first English textbook on this subject, further promoting traditional Chinese medicine globally [6]